赛尼哌预防肾移植术后急性排斥反应的应用研究  

Zenapax in the prevention of acute renal allograft rejection

作　　者：热衣汉.西里甫 刘健[1] 桑晓红[1] 米娜瓦尔.玉诺斯 

机构地区：[1]新疆医科大学第一附属医院肾病科,新疆乌鲁木齐830011

出　　处：《新疆医科大学学报》2009年第7期906-908,共3页Journal of Xinjiang Medical University

摘　　要：目的:探讨赛尼哌诱导治疗,预防同种异体肾移植术后急性排斥的有效性和安全性。方法:回顾分析已随诊1年的46例应用赛尼哌的肾移植患者(赛尼哌组)临床效果,并以同期肾移植患者未用赛尼哌治疗的66例作为对照组,对照组未进行其它治疗。赛尼哌组(商品名:达利珠单抗;由上海罗氏制药有限公司提供)。所有患者均在术中血管开放前1 h使用,第2剂用法相同,在术后第14天给药。对2组术后急性排斥反应、术后感染、白细胞减少等并发症发生情况。结果:赛尼哌组在3个月内急性排斥反应发生率8.6%。显著低于对照组(21.2%,P<0.05),差异有统计学意义。2组在感染及副作用发生率差异无统计学意义(P>0.05)。结论:对2剂赛尼哌加上CsA、Pred,联合应用的急性抑制方案可以有效预防同种尸体肾移植患者的急性排斥反应的发生,能明显降低而不增加肾移植术后急性感染、白细胞减少等并发症。Objective： To investigate the validity and safety of zenapax in the prevention of acute rejection in renal transplant recipients. Methods： The medical records of 46 renal transplant recipients treated with two doses of zenapax （study group） and simultaneously 66 renal transplant recipients without treatment of zenapax （control group） were retrospectively analyzed. The following-up was one year. The incidence of a- cute rejection, postoperative infection leukopenia and other complications were comparatively analyzed between the 2 groups. Results： Acute rejection rate was lower in study group （8.6%） compared with that in control group （21. 2%; P 〈0. 05）. The differences of adverse events and infection rate between the 2 groups were not significant （P 〉0.05）. Conclusions： Two doses regimen of zenapax add CsA, Pred as part of immunosuppressive therapy is effective in the prevention of acute rejection in renal transplant recipients. It can markedly reduce but not increase postoperative infection, leukopenia and other complications.

关 键 词：肾移植 赛尼哌 急性排斥反应 

分 类 号：R979.5[医药卫生—药品] R617[医药卫生—药学]